Yield10 Bioscience Gestion

Gestion contrôle des critères 3/4

Le PDG Yield10 Bioscience est Olly Peoples, nommé en Oct2016, a un mandat de 8.08 ans. La rémunération annuelle totale est $ 598.55K, composée du salaire de 57.5% et des bonus 42.5%, y compris les actions et options de la société. détient directement 3.02% des actions de la société, d'une valeur de $ 12.33K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 8.1 ans et 12.9 ans.

Informations clés

Olly Peoples

Directeur général

US$598.6k

Rémunération totale

Pourcentage du salaire du PDG	57.5%
Durée du mandat du directeur général	8.1yrs
Propriété du PDG	3.0%
Durée moyenne d'occupation des postes de direction	8.1yrs
Durée moyenne du mandat des membres du conseil d'administration	12.9yrs

Mises à jour récentes de la gestion

Recent updates

Yield10 Bioscience GAAP EPS of $0.70 beats by $1.39, revenue of $0.1M misses by $0.06M

Aug 10

Is Yield10 Bioscience (NASDAQ:YTEN) In A Good Position To Invest In Growth?

Nov 12

Yield10 Bioscience (NASDAQ:YTEN) Is In A Good Position To Deliver On Growth Plans

Jul 19

Yield10 Bioscience, Inc.'s (NASDAQ:YTEN) CEO Will Probably Find It Hard To See A Huge Raise This Year

May 18

Here's Why We're Watching Yield10 Bioscience's (NASDAQ:YTEN) Cash Burn Situation

Apr 14

Analyse de la rémunération des PDG

Comment la rémunération de Olly Peoples a-t-elle évolué par rapport aux bénéfices de Yield10 Bioscience?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-US$13m
Mar 31 2024	n/a	n/a	-US$13m
Dec 31 2023	US$599k	US$344k	-US$14m
Sep 30 2023	n/a	n/a	-US$14m
Jun 30 2023	n/a	n/a	-US$14m
Mar 31 2023	n/a	n/a	-US$14m
Dec 31 2022	US$527k	US$331k	-US$14m
Sep 30 2022	n/a	n/a	-US$13m
Jun 30 2022	n/a	n/a	-US$12m
Mar 31 2022	n/a	n/a	-US$12m
Dec 31 2021	US$2m	US$315k	-US$11m
Sep 30 2021	n/a	n/a	-US$11m
Jun 30 2021	n/a	n/a	-US$10m
Mar 31 2021	n/a	n/a	-US$9m
Dec 31 2020	US$1m	US$289k	-US$10m
Sep 30 2020	n/a	n/a	-US$14m
Jun 30 2020	n/a	n/a	-US$14m
Mar 31 2020	n/a	n/a	-US$14m
Dec 31 2019	US$600k	US$275k	-US$13m
Sep 30 2019	n/a	n/a	-US$8m
Jun 30 2019	n/a	n/a	-US$9m
Mar 31 2019	n/a	n/a	-US$9m
Dec 31 2018	US$738k	US$275k	-US$9m
Sep 30 2018	n/a	n/a	-US$11m
Jun 30 2018	n/a	n/a	-US$11m
Mar 31 2018	n/a	n/a	-US$11m
Dec 31 2017	US$382k	US$225k	-US$11m

Rémunération vs marché: La rémunération totale de Olly ($USD 598.55K ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 653.78K ).

Rémunération et revenus: La rémunération de Olly a augmenté alors que l'entreprise n'est pas rentable.

PDG

Olly Peoples (66 yo)

8.1yrs

Titularisation

US$598,554

Compensation

Dr. Oliver P. Peoples, also known as Olly, Ph D., is a Co-founder of Metabolix Inc., and has been its Chief Executive Officer and President since October 17, 2016. Dr. Peoples served as its Chief Scientifi...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Oliver Peoples	Co-Founder	8.1yrs	US$598.55k	3.02% $ 12.3k
Kristi Snell	VP of Research & Chief Science Officer	8.1yrs	US$406.26k	1.98% $ 8.1k
Lynne Brum	VP of Planning & Corporate Communications and Secretary	8.1yrs	US$366.98k	1.81% $ 7.4k
Charles Haaser	VP of Finance	10yrs	US$251.94k	0.87% $ 3.5k

8.1yrs

Durée moyenne de l'emploi

63yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de YTEN est chevronnée et expérimentée (8.1 années d'ancienneté moyenne).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Oliver Peoples	Co-Founder	32.4yrs	US$598.55k	3.02% $ 12.3k
Richard Hamilton	Independent Director	7.7yrs	US$74.84k	0.44% $ 1.8k
Robert Van Nostrand	Independent Chairman of the Board	18.1yrs	US$84.84k	0.29% $ 1.2k
Anthony Sinskey	Independent Director	32.4yrs	US$74.84k	0.39% $ 1.6k
Sherri Brown	Independent Director	4.8yrs	US$57.34k	0% $ 0
Willie Loh	Independent Director	2.1yrs	US$57.34k	0% $ 0

12.9yrs

Durée moyenne de l'emploi

66.5yo

Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la YTEN est chevronné et expérimenté ( 12.9 années d'ancienneté moyenne).

Yield10 Bioscience Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Yield10 Bioscience, Inc., Annual General Meeting, Jun 07, 2024

Insider recently bought US$1m worth of stock

Yield10 Bioscience, Inc. Appoints Willie Loh to Its Board of Directors

Yield10 Bioscience, Inc. Appoints Willie Loh to Its Board of Directors

Yield10 Bioscience, Inc., Annual General Meeting, May 25, 2022

Yield10 Bioscience, Inc., Annual General Meeting, May 25, 2022

Recent updates

Nuseed Nutritional US Inc. entered into an asset purchase agreement to acquire Substantially all assets of Yield10 Bioscience, Inc./Yield10 Oilseeds, Inc. from Yield10 Bioscience, Inc. (OTCPK:YTEN) and Yield10 Oilseeds, Inc. for $5 million.

Yield10 Bioscience, Inc.(OTCPK:YTEN) dropped from NASDAQ Composite Index

Yield10 Bioscience Announces Delisting from Nasdaq

Yield10 Bioscience Announces 1-for-24 Reverse Stock Split to Increase the Market Price Per Share of the its Common Stock to Maintain the Listing of its Common Stock on The Nasdaq Capital Market

Yield10 Bioscience, Inc., Annual General Meeting, Jun 07, 2024

Yield10 Bioscience Receives Written Notice from The Nasdaq Stock Market LLC Regarding Not Eligible for Second 180 Day Compliance Period for the Minimum Bid Price Rule Deficiency

Yield10 Bioscience, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Yield10 Bioscience, Inc. Announces the Plant Biosafety Office of the Canadian Food Inspection Agency Clear Genome-edited E3902 Camelina for Planting in Canada

Nasdaq Hearings Panel Grants Yield10 Bioscience, Inc. an Additional Extension to Remain Listed on the Nasdaq Capital Market Until May 13, 2024

Yield10 Bioscience, Inc. Provides an Update on Its Omega-3 Camelina Program

Yield10 Bioscience, Inc. Files Request for Regulatory Status Review with USDA-APHIS for Camelina Designed to Produce the EPA and DHA Components of Omega-3 Oil

Yield10 Bioscience Receives Non-Compliance Notice From Nasdaq

Yield10 Bioscience, Inc. Contemplates Bankruptcy.

Yield10 Bioscience, Inc. Contemplates Bankruptcy.

Yield10 Bioscience, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Yield10 Bioscience, Inc. Provides Update on Recent Advancements in the Development of Elite Herbicide Tolerant Camelina

Yield10 Bioscience, Inc. Receives Non-Compliance Notice from Nasdaq

Yield10 Bioscience, Inc. has completed a Composite Units Offering in the amount of $3.7375 million.

Price target decreased by 33% to US$9.83

Second quarter 2023 earnings released: US$0.64 loss per share (vs US$0.70 loss in 2Q 2022)

New major risk - Shareholder dilution

Yield10 Bioscience, Inc. to Report Q2, 2023 Results on Aug 14, 2023

New major risk - Market cap size

Yield10 Bioscience, Inc. Announces Positive Results in the First Field Test of Stacked Herbicide Tolerance Traits in Camelina

New minor risk - Share price stability

Yield10 Bioscience Files Request for Regulatory Status Review Under Usda-Aphis’S Secure Rule Covering Elite Camelina Designed to Produce the EPA Component of Omega-3 Oil

Yield10 Bioscience Receives A Deficiency Letter from Nasdaq Regarding Minimum Stockholders' Equity Requirement for Continued Listing on the Nasdaq Capital Market

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Insider recently bought US$1m worth of stock

Yield10 Bioscience, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$14.67

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$14.67

Yield10 Bioscience, Inc. Begins Winter 2022/2023 Field Test and Seed Production Program

Yield10 Bioscience, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Yield10 Bioscience, Inc. Appoints Willie Loh to Its Board of Directors

Yield10 Bioscience, Inc. Appoints Willie Loh to Its Board of Directors

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Yield10 Bioscience GAAP EPS of $0.70 beats by $1.39, revenue of $0.1M misses by $0.06M

Yield10 Bioscience, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Yield10 Bioscience, Inc. to Report Q1, 2022 Results on May 11, 2022

Price target decreased to US$15.33

Yield10 Bioscience, Inc., Annual General Meeting, May 25, 2022

Yield10 Bioscience, Inc., Annual General Meeting, May 25, 2022

Price target decreased to US$17.00

Yield10 Bioscience Announces Recent Advances in the Development of Camelina as A Production Platform for PHA Bioplastic

Yield10 Bioscience, Inc. Announces an Update on the Camelina Line E3902 Development Program

Yield10 Bioscience, Inc. to Report Q4, 2021 Results on Mar 09, 2022

Is Yield10 Bioscience (NASDAQ:YTEN) In A Good Position To Invest In Growth?

Third quarter 2021 earnings released: US$0.49 loss per share (vs US$0.87 loss in 3Q 2020)

Consensus revenue estimates fall to US$890.0k

Price target decreased to US$21.50

Second quarter 2021 earnings released: US$0.64 loss per share (vs US$0.92 loss in 2Q 2020)

Yield10 Bioscience (NASDAQ:YTEN) Is In A Good Position To Deliver On Growth Plans

Yield10 Bioscience, Inc. Begins 2021 Field Test and Seed Scale Up Program

Yield10 Bioscience, Inc.'s (NASDAQ:YTEN) CEO Will Probably Find It Hard To See A Huge Raise This Year

Consensus revenue estimates fall to US$1.08m

First quarter 2021 earnings released: US$0.60 loss per share (vs US$2.12 loss in 1Q 2020)

Here's Why We're Watching Yield10 Bioscience's (NASDAQ:YTEN) Cash Burn Situation

Consensus forecasts updated

Full year 2020 earnings released: US$4.30 loss per share (vs US$35.50 loss in FY 2019)

Yield10 Bioscience, Inc. to Report Q4, 2020 Results on Mar 16, 2021

New 90-day high: US$18.86

Yield10 Bio secures $12.7M capital raise

Yield10 Bioscience under pressure on launching stock offering